Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project
Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance between senescence and cell growth
DALLAS, Texas, March 06, 2024 – Colossal Biosciences, the world’s first de-extinction company, announced that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough. This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation. [Read more…]
How Human iPSCs are Revolutionizing Drug Discovery in 2024
Drug discovery involves high cost and uncertain outcomes. Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerge during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.
Now, some new medicines are being tested for safety on specialized cells developed from human pluripotent cell lines. Cell types which are frequently being using within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]
Development of iPSC-derived Disease Models
Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment[3]. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
Allogeneic iPSCs Gaining Momentum Due to Ease of Access and Economies of Scale
While autologous iPSC-based cell therapies are patient-specific, allogeneic iPSC-based cell therapies use donor-derived cells as a starting material. In recent years, a greater number of allogeneic iPSC-derived cell therapies are being studied than autologous therapies. One of the advantages of allogeneic therapy is that a large number of doses can be generated simultaneously from a single batch of iPSCs and banked. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 68
- Next Page »